Oruka Therapeutics Inc [ORKA] stock is trading at $12.6, down -0.08%. An important factor to consider is whether the stock is rising or falling in short-term value. The ORKA shares have gain 8.34% over the last week, with a monthly amount glided 5.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Oruka Therapeutics Inc [NASDAQ: ORKA] stock has seen the most recent analyst activity on May 22, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $44. Previously, Wolfe Research started tracking the stock with Outperform rating on February 04, 2025, and set its price target to $20. On October 11, 2024, Stifel initiated with a Buy rating and assigned a price target of $49 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $45 on October 07, 2024. Leerink Partners initiated its recommendation with a Outperform and recommended $44 as its price target on September 17, 2024. In a note dated September 13, 2024, Jefferies initiated an Buy rating and provided a target price of $40 on this stock.
Oruka Therapeutics Inc [ORKA] stock has fluctuated between $5.49 and $33.00 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Oruka Therapeutics Inc [NASDAQ: ORKA] shares were valued at $12.6 at the most recent close of the market. An investor can expect a potential return of 58.73% based on the average ORKA price forecast.
Analyzing the ORKA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.27 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.16 points at the first support level, and at 11.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.98, and for the 2nd resistance point, it is at 13.37.
Ratios To Look Out For
For context, Oruka Therapeutics Inc’s Current Ratio is 30.03. On the other hand, the Quick Ratio is 30.03, and the Cash Ratio is 7.13.
Transactions by insiders
Recent insider trading involved Venrock Healthcare Capital Par, 10% Owner, that happened on Feb 14 ’25 when 88794.0 shares were purchased. 10% Owner, Venrock Healthcare Capital Par completed a deal on Feb 13 ’25 to buy 14950.0 shares. Meanwhile, 10% Owner Venrock Healthcare Capital Par bought 8971.0 shares on Feb 12 ’25.
